ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

regorafenib

Also written as “Regorafenib (Stivarga, BAY73-4506)”, “Regorafenib” and “Regorafenib (BAY73-4506)”.

Its studies are mostly in Colorectal Neoplasms · Neoplasms · Carcinoma, Hepatocellular · Pancreatic Neoplasms · Squamous Cell Carcinoma of Head and Neck, led by 2 companies.

Drug pageRegorafenib: every studyAll 173 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since May 24, 201833 company-led studies, 1 open or runningNext primary completion: Apr 27, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bayer321 open or runningphase 4since May 24, 2018Apr 17, 2008Apr 27, 2028phase 2 · NCT06246643
Sarah Cannon Research Instituteits history only10 open or runningphase 2since Apr 21, 2015Apr 21, 2015none ahead

Also a collaborator on its studies: Novartis, Merck, Bristol-Myers Squibb and Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bayer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 17 studies since Apr 17, 2008.

  1. Sep 6, 2013Phase 3 study in Colorectal NeoplasmsNCT01939223 · 25 enrolled · United States, Australia, Belgium and more
  2. Oct 28, 2013Phase 1 study in NeoplasmsNCT01973868 · 42 enrolled · United States
  3. Nov 28, 2013Phase 1 study in NeoplasmsNCT02001909 · 27 enrolled · Germany
  4. Mar 7, 2014Phase 1 study in NeoplasmsNCT02085148 · 62 enrolled · France, Italy, Spain and more
  5. Apr 4, 2014Phase 1 study in NeoplasmsNCT02106845 · 42 enrolled · Germany, Hungary
  6. Aug 20, 2014Phase 2 study in Macular DegenerationNCT02222207 · 52 enrolled · United States, Australia, Austria and more
  7. Mar 20, 2015Phase 1 study in NeoplasmsNCT02398513 · 18 enrolled · China
  8. Jun 4, 2015Phase 2 study in Colorectal NeoplasmsNCT02465502 · 59 enrolled · Brazil
  9. Nov 16, 2017Phase 1 study in Carcinoma, HepatocellularNCT03347292 · 58 enrolled · United States, Germany
  10. May 24, 2018Phase 4 study in Colorectal NeoplasmsNCT03564938 · 100 enrolled · India
  11. Mar 25, 2019Phase 2 study in Colorectal NeoplasmsNCT03890731 · 6 enrolled · United States, Germany, Italy and more
  12. Oct 11, 2019Phase 2 study in Colorectal NeoplasmsNCT04126733 · 70 enrolled · United States
  13. Jan 4, 20212 phase 2 studiesNCT04696055, NCT04704154
  14. Jan 14, 2024Phase 2 study in Solid Malignant TumorsNCT06246643 · 13 enrolled · France, Japan, South Korea and more

Ahead

  1. Apr 27, 2028Primary completion: phase 2 study in Solid Malignant TumorsNCT06246643

TargetBeta

“Tyrosine-protein kinase ABL inhibitor; Serine/threonine-protein kinase RAF inhibitor; Stem cell growth factor receptor inhibitor; Fibroblast growth factor receptor 1 inhibitor”ChEMBL 37, by rule

Studies

All 32 Bayer leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06246643Solid Malignant Tumors · France, Japan, South Korea and more2Active, not recruitingApr 27, 202813
NCT04704154Squamous Cell Carcinoma of Head and Neck · United States, Belgium, France and more2CompletedMar 9, 2023175
NCT04696055Carcinoma, Hepatocellular · United States, France, Germany and more2CompletedMay 5, 202295
NCT04126733Colorectal Neoplasms · United States2CompletedNov 11, 202070
NCT03890731Colorectal Neoplasms · United States, Germany, Italy and more2CompletedFeb 28, 20236
NCT03564938Colorectal Neoplasms · India4CompletedMar 20, 2023100
NCT03347292Carcinoma, Hepatocellular · United States, Germany1CompletedDec 17, 202058
NCT02465502Colorectal Neoplasms · Brazil2CompletedMay 2, 201759
NCT02398513Neoplasms · China1CompletedNov 201518
NCT02222207Macular Degeneration · United States, Australia, Austria and more2TerminatedMay 201552
NCT02106845Neoplasms · Germany, Hungary1CompletedApr 27, 201542
NCT02085148Neoplasms · France, Italy, Spain and more1CompletedMay 5, 201962
NCT02001909Neoplasms · Germany1CompletedApr 201427
NCT01973868Neoplasms · United States1CompletedJan 31, 201742
NCT01939223Colorectal Neoplasms · United States, Australia, Belgium and more3TerminatedAug 29, 201625
NCT01853046Neoplasms · United States, Canada1CompletedJul 201524
NCT01853319Colorectal Neoplasms · Turkey3CompletedApr 24, 2015100
NCT01774344Carcinoma, Hepatocellular · United States, Argentina, Australia and more3CompletedFeb 29, 2016573
NCT01584830Colorectal Neoplasms · China, Hong Kong, Korea, Republic of and more3CompletedNov 2013204
NCT01339104Neoplasms · United States1CompletedAug 201353
NCT01318265Pharmacokinetics · United States1CompletedJul 201124
NCT01289821Colorectal Neoplasms · United States, Australia, Belgium and more2CompletedMar 201254
NCT01271712Gastrointestinal Stromal Tumors · United States, Austria, Belgium and more3CompletedJan 26, 2012199
NCT01187615Small Cell Lung Carcinoma · United States1TerminatedJun 20129
NCT01103323Colorectal Neoplasms · United States, Argentina, Australia and more3CompletedJul 2011760
NCT01096030Neoplasms · Hong Kong, Singapore1CompletedNov 201233
NCT01117623Neoplasms · United States1CompletedNov 201386
NCT01002378Dietary Fats · United States1CompletedFeb 201024
NCT01003015Carcinoma, Hepatocellular · Germany, Italy, Korea, Republic of and more2CompletedNov 201036
NCT00960258Neoplasms · Japan1CompletedApr 26, 201015
NCT00934882Colorectal Neoplasms · Germany1CompletedApr 201245
NCT00664326Carcinoma, Renal Cell · United States, Finland, France and more2CompletedMay 31, 200949

How it is read

Names in the registry

  • “Regorafenib (Stivarga, BAY73-4506)”, 21 entries
  • “Regorafenib”, 6 entries
  • “Regorafenib (BAY73-4506)”, 4 entries
  • “TAS-102, Regorafenib , Fruquintinib”, 1 entry
  • “Regorafenib, (Stivarga, BAY73-4506)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.